JOURNAL HOME CME HOME THIS MONTH PAST ISSUES ETOC COLLECTIONS
AUTHORS REVIEWERS EDITORIAL BOARD FEEDBACK RSS HELP
A&A International Anesthesia Research Society
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bina, S.
Right arrow Articles by Muldoon, S. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bina, S.
Right arrow Articles by Muldoon, S. M.
Related Collections
Right arrow Monitoring (Non-cardiac)
Right arrow Pharmacology

Anesth Analg 2003;96:153-158
© 2003 International Anesthesia Research Society


ANESTHETIC PHARMACOLOGY

Extending the Skeletal Muscle Viability Period in the Malignant Hyperthermia Test

Saiid Bina, PhD, Stephen Holman, MD, and Sheila M. Muldoon, MD

Department of Anesthesiology, Uniformed Services University of the Health Sciences, Bethesda, Maryland

Address correspondence and reprint requests to Saiid Bina, PhD, Department of Anesthesiology, USUHS, 4301 Jones Bridge Rd., Bethesda, MD 20814. Address e-mail to sbina{at}usuhs.mil

The caffeine halothane contracture test (CHCT) is the only validated test for diagnosing malignant hyperthermia (MH) susceptibility (MHS) and phenotyping MHS families. Although most diagnostic laboratory tests can check intra- and interlaboratory consistency through the use of standard control samples, there has been no practical way to achieve this goal for the CHCT. The distances between diagnostic centers and time constraints of the CHCT protocol (5 h) prohibit centers from sharing tissue samples. In this study, we investigated varying storage conditions to extend the standard viability period of skeletal muscle to 24 h. Twenty MHS patients were tested according to the North America protocol. After standard CHCT, the surplus muscle samples were placed in one of the following four treatment groups. In Groups 1 and 2, muscles remained under tension and were stored in Krebs buffer (pH 7.4) at 23°C–25°C (clamped-warm) and 4°C (clamped-cold), respectively. In Groups 3 and 4, muscle strips were dissected, and the ends were tied with silk sutures, cut from the clamp, and placed in Krebs buffer at 23°C–25°C (free-warm) and 4°C (free-cold), respectively. The responses of the treatment groups to halothane (3%) and caffeine (0.5–32 mM) were tested at 22–26 h after excision. The clamped-warm storage group correctly diagnosed MHS in all patients.

IMPLICATIONS: Varying conditions for storage of muscle were investigated to extend the viability period of muscle in the malignant hyperthermia (MH) test from 5 to 24 h. Muscles stored for 24 h under tension at room temperature remained viable and correctly diagnosed MH susceptibility in all patients.







Lippincott, Williams & Wilkins Anesthesia & Analgesia® is published for the International Anesthesia Research Society® by Lippincott Williams & Wilkins and Stanford University Libraries' HighWire Press®. Copyright 2003 by the International Anesthesia Research Society. Online ISSN: 1526-7598   Print ISSN: 0003-2999 HighWire Press
Copyright © 2003 by the International Anesthesia Research Society.